Top-News

LIDDS AB News

Aktie
WKN:  A12DLG ISIN:  SE0001958612
0,0036 €
+0,0004 €
+12,50%
08:12:07 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

LIDDS AB News

11.03.22 - GlobeNewswire
Report from Extraordinary General Meeting in LIDDS
UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary ...
04.03.22 - GlobeNewswire
LIDDS publishes agenda for the company's Capital Markets Day 2022
UPPSALA, SWEDEN – LIDDS AB (publ) announced today the agenda for the Capital Markets Day to be held on March 9, 2022, for investors, analysts and media.
24.02.22 - GlobeNewswire
Statement from LIDDS regarding convertible note agreement
UPPSALA, SWEDEN – LIDDS announced 22 February 2022 that the company had entered into a convertible note agreement with Nice & Green, a Swiss specialty investor, and the ...
23.02.22 - GlobeNewswire
LIDDS AB (publ) Year-end report 2021
October – December
22.02.22 - GlobeNewswire
Notice of Extraordinary General Meeting in LIDDS AB (publ)
The shareholders in LIDDS AB (publ) (reg. no. 556580-2856) (the “ Company ” or “ LIDDS ”) are hereby convened to the Extraordinary General Meeting on Friday, 11 March 2022 at ...
22.02.22 - GlobeNewswire
LIDDS secures financing of up to 40.8 MSEK to create foundation for new partnerships based on the NanoZolid® technology
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company has entered into a convertible note agreement with Nice & Green (“N&G”), a Swiss specialty investor with ...
21.02.22 - GlobeNewswire
LIDDS Next Step with NanoZolid® formulated docetaxel
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical ...
17.02.22 - GlobeNewswire
Invitation to LIDDS Capital Markets Day and presentation of new strategy and vision
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company will host a Capital Markets Day on March 9, 2022, for investors, analysts and media. The presentation will ...
14.01.22 - GlobeNewswire
LIDDS presents at Redeye Fight Cancer Seminar
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022.
11.01.22 - GlobeNewswire
LIDDS announces successful stage 1 in R&D project
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the R&D project with Johnson & Johnson Enterprise Innovation Inc. has progressed into next phase .
29.12.21 - GlobeNewswire
LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study ...
20.12.21 - GlobeNewswire
LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years ...
17.12.21 - GlobeNewswire
LIDDS patent covering the NanoZolid® production process granted in China
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has ...
22.11.21 - GlobeNewswire
LIDDS Interim report January – September 2021
JANUARY – SEPTEMBER 2021
17.11.21 - GlobeNewswire
Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
November 17, 2021
15.11.21 - GlobeNewswire
LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive ...
04.10.21 - GlobeNewswire
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study ...
28.09.21 - GlobeNewswire
LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
06.07.21 - GlobeNewswire
LIDDS – subscription of warrants
UPPSALA, SWEDEN – LIDDS AB (publ)
28.05.21 - GlobeNewswire
LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that LIDDS new CEO Nina Herne will hold her first presentation at Redeye’s Growth Day on June 2 at 13.50 pm CET.

Newssuche

Videos

newspaper
07.05.24 +2,66%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »